Physician profile
Devnandini Rastogi
NPI 1710903935
$260,807.22
in general payments reported to CMS, 2019-2025
6 companies · $53K in 2025
The $53K reported for 2025 was more than what 98% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $34K · 2020: $15K · 2021: $17K · 2022: $25K · 2023: $41K · 2024: $77K · 2025: $53K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $132K · Consulting Fee: $18K · Travel and Lodging: $15K · Food and Beverage: $5,530.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $132,013.25 |
| Consulting Fee | $17,622.00 |
| Travel and Lodging | $15,480.98 |
| Food and Beverage | $5,529.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $90,813.10 | 2019-2025 | Invega Sustenna, Invega Trinza, Invega |
| Otsuka America Pharmaceutical, INC. | $82,878.06 | 2019-2025 | Abilify Maintena, Abilify Asimtufii |
| E.R. Squibb & Sons, L.L.C. | $50,442.95 | 2024-2025 | Cobenfy |
| Alkermes, INC. | $29,519.82 | 2019-2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $6,920.86 | 2025 | Caplyta |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $232.43 | 2019-2025 | Abilify Asimtufii, Abilify Maintena, Rexulti |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Devnandini Rastogi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.